Condition: Generalized Myasthenia Gravis · Anti-AChR Antibody Positive · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Bergamo, Italy | Recruiting |
| Clinical Trial Site | Bologna, Italy | Not Yet Recruiting |
| Clinical Trial Site | Bologna, Italy | Recruiting |
| Clinical Trial Site | Brescia, Italy | Recruiting |
| Clinical Trial Site | Florence, Italy | Recruiting |
| Clinical Trial Site | Imperia, Italy | Not Yet Recruiting |
| Clinical Trial Site | Lecco, Italy | Recruiting |
| Clinical Trial Site | Messina, Italy | Not Yet Recruiting |
| Clinical Trial Site | Milan, Italy | Recruiting |
| Clinical Trial Site | Milan, Italy | Not Yet Recruiting |
| Clinical Trial Site | Naples, Italy | Not Yet Recruiting |
| Clinical Trial Site | Novara, Italy | Not Yet Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06967480